A 42-year-old woman on warfarin for atrial fibrillation (INR 3.2 today) presents with moderate epistaxis from the right nostril that began 30 minutes ago. She denies recent nasal trauma or surgery. On examination, blood pressure is 128/82 mmHg, heart rate 88 bpm, and anterior rhinoscopy shows active bleeding from the anteroinferior septum. After topical epinephrine application and gentle compression for 10 minutes, bleeding stops. What is the most appropriate management at this point?

Explanation

## Clinical Context This patient has **anticoagulation-related epistaxis** with an **elevated INR (3.2)** on warfarin. Although bleeding has temporarily stopped, the underlying coagulopathy remains uncorrected, placing her at **high risk for recurrence**. **Key Point:** Epistaxis in an anticoagulated patient requires **reversal of the coagulopathy** in addition to local hemostasis. ## Management of Anticoagulation-Related Epistaxis | Factor | Fresh Frozen Plasma (FFP) | Vitamin K1 (Phytonadione) | Prothrombin Complex Concentrate (PCC) | | --- | --- | --- | --- | | **Onset of action** | Immediate (minutes) | 12–24 hours | 30 minutes–2 hours | | **Volume required** | 10–15 mL/kg (large) | 5–10 mg IV | 25–50 units/kg | | **Risk of volume overload** | High | None | Low | | **Current role in epistaxis** | Bridging only (if PCC unavailable) | First-line reversal agent | Preferred if available | | **Mechanism** | Replaces all vitamin K–dependent factors | Replenishes hepatic vitamin K stores | Concentrates factors II, VII, IX, X | **High-Yield:** For warfarin reversal in epistaxis, **vitamin K1 (phytonadione) 5–10 mg IV is the standard agent** because: - It addresses the **underlying cause** (vitamin K deficiency) - It provides **sustained reversal** (effect lasts 24–48 hours) - It avoids **volume overload** (important in elderly or cardiac patients) - FFP is reserved for **emergency situations** (e.g., intracranial hemorrhage) where immediate reversal is critical **Clinical Pearl:** FFP alone does NOT correct the underlying vitamin K deficiency and provides only **transient reversal** (4–6 hours). Vitamin K1 must be given concurrently for sustained effect. ## Why Anterior Nasal Packing? Even though bleeding has stopped, packing serves as **prophylaxis against recurrence** in the setting of ongoing anticoagulation. The patient should be admitted for: 1. Observation for re-bleeding (24 hours minimum) 2. Confirmation that INR has normalized after vitamin K1 3. Safe removal of packing (typically after 24–48 hours) ## Why Not Discharge Home? Discharging without reversing warfarin and without packing leaves the patient at **high risk for recurrent, potentially severe epistaxis** at home. The temporary cessation of bleeding does not mean the coagulopathy has resolved. ## Why Not FFP Instead of Vitamin K1? FFP provides only **transient reversal** and carries risk of **volume overload**, particularly in a patient with atrial fibrillation (who may have underlying cardiac disease). Vitamin K1 is the definitive agent for warfarin reversal in non-emergent situations. ## Why Not Continue Warfarin Without Reversal? Continuing warfarin with an INR of 3.2 in the setting of active epistaxis perpetuates the coagulopathy and virtually guarantees recurrence. Warfarin must be held and INR reversed before discharge. ```mermaid flowchart TD A[Epistaxis on Warfarin]:::outcome --> B{INR level?}:::decision B -->|INR < 4<br/>Minor bleed| C[Hold warfarin<br/>Vitamin K1 2.5-5 mg IV]:::action B -->|INR 4-10<br/>Moderate bleed| D[Hold warfarin<br/>Vitamin K1 5-10 mg IV<br/>Consider PCC if urgent]:::action B -->|INR > 10<br/>Major bleed| E[Vitamin K1 10 mg IV<br/>PCC 25-50 units/kg<br/>FFP if PCC unavailable]:::urgent C --> F[Local hemostasis<br/>Anterior packing]:::action D --> F E --> F F --> G[Admit 24 hrs<br/>Monitor INR]:::action G --> H[Remove packing<br/>when INR normalized]:::action H --> I[Discharge with<br/>anticoagulation plan]:::outcome ```